The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent to 30 different telehealth companies that market compounded versions of ...

March 3 (Reuters) - The U.S. Food and Drug Administration has issued warning letters to 30 telehealth companies for making ...

The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of ...

The FDA has issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products on their websites. The letters cite violations including claims ...

The FDA’s effort to crack down on compounded versions of popular GLP-1 weight-loss drugs has sparked backlash from patients and compounding pharmacies over concerns about access and ...

1. FDA. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. FDA News Release. March 3, 2026.

A bipartisan bill at the state capitol in Denver is targeting compounded versions of popular weight loss drugs like Ozempic, Wegovy, and Zepbound, known as GLP-1s.

Compounded GLP-1s for Weight Loss: What Are They and Are They Safe? GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably heard ...

Part of "a new era of enforcement," says FDA chief ...